LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer

"This is the 15th year [of LUGPA,] and I think I've gone maybe 12, 13 years in a row or so, almost every year," says Lawrence Gervasi, MD.

"This is our biggest meeting ever in our 15-year history [with] almost 1100 people here," says Evan R. Goldfischer, MD, MBA, FACS.

"Patients shouldn’t be making the decision to do active surveillance without understanding what that means and what their other options are,” one panelist said.

“Radiation therapy continues to expand its role, especially if you start talking about [patients with] the ultra high–risk [prostate cancer] or node-positive [disease] and beyond,” says Daniel Spratt, MD.

“We went to medical school to take care of patients, not to service the computer, which is what we do for a large part of our daily work," said Inderbir Gill, MD.

“There’s a lot of clinical trial activity in the [bladder cancer realm], and hopefully [new therapies will] keep adding to our armamentarium of [treatment strategies] we can offer patients,” said Gautam Jayram, MD.